1. Home
  2. ICFI vs DMRA Comparison

ICFI vs DMRA Comparison

Compare ICFI & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICF International Inc.

ICFI

ICF International Inc.

HOLD

Current Price

$67.14

Market Cap

1.8B

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$22.00

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ICFI
DMRA
Founded
1969
2011
Country
United States
United States
Employees
N/A
7
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
ICFI
DMRA
Price
$67.14
$22.00
Analyst Decision
Buy
Buy
Analyst Count
4
2
Target Price
$99.25
$43.00
AVG Volume (30 Days)
205.1K
316.7K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
0.82%
N/A
EPS Growth
N/A
N/A
EPS
1.12
N/A
Revenue
$1,229,162,000.00
N/A
Revenue This Year
$4.12
N/A
Revenue Next Year
$5.33
N/A
P/E Ratio
$59.61
N/A
Revenue Growth
3.72
N/A
52 Week Low
$58.83
$16.50
52 Week High
$101.71
$28.76

Technical Indicators

Market Signals
Indicator
ICFI
DMRA
Relative Strength Index (RSI) 40.05 41.75
Support Level $64.43 $18.59
Resistance Level $75.03 $27.70
Average True Range (ATR) 2.55 1.99
MACD -0.09 -0.06
Stochastic Oscillator 6.42 36.16

Price Performance

Historical Comparison
ICFI
DMRA

About ICFI ICF International Inc.

ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: